RGEN Repligen Corporation

45.34
+1.14  (3%)
Previous Close 44.20
Open 44.41
Price To book 8.52
Market Cap 1.55B
Shares 34,080,000
Volume 726,257
Short Ratio 13.15
Av. Daily Volume 261,875

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 17930653
  2. 8-K/A [Amend] - Current report 17930571
  3. 8-K - Current report 17926361
  4. 8-K - Current report 17864592
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17813162

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL received June 22, 2012.
RG1068
Detection of pancreatic duct abnormalities

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 17930653
  2. 8-K/A [Amend] - Current report 17930571
  3. 8-K - Current report 17926361
  4. 8-K - Current report 17864592
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17813162
  6. 8-K - Current report 17811888
  7. DEF 14A - Other definitive proxy statements 17776266
  8. PRE 14A - Other preliminary proxy statements 17749702
  9. UPLOAD [Cover] - SEC-generated letter
  10. 8-K/A [Amend] - Current report 17654032